Jyoti Nangalia | Cancer Research UK Clinician Scientist

Nangalia, Jyoti

Jyoti is a CRUK Clinician Scientist and Consultant Haematologist. She utilises sequencing technologies to help understand why blood cancers originate and evolve, and how this relates to normal development and ageing.


  • Pathogenesis of Myeloproliferative Disorders.

    Nangalia J, Grinfeld J and Green AR

    Annual review of pathology 2016;11;101-26

  • DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

    Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J et al.

    Haematologica 2015;100;11;e438-42

  • Effect of mutation order on myeloproliferative neoplasms.

    Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC et al.

    The New England journal of medicine 2015;372;7;601-612

  • MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.

    Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A et al.

    Leukemia 2015;29;2;494-7

  • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

    Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G et al.

    The New England journal of medicine 2013;369;25;2391-2405

Nangalia, Jyoti
Jyoti's Timeline

Advanced Research Grant | European Haematology Association

Cancer Research UK Clinician Scientist Fellowship


PhD awarded | University of Cambridge

Completion of Specialist Training | Haematology

Translational Research Training in Haematology Fellow | ASH-EHA | Class of 2015


Johnstone & Florence Stoney Scholarship | British Federation of Women Graduates


PhD commenced | University of Cambridge


Member of the Royal College of Pathologists


Academic Clinical Fellow | Haematology | East of England


MB BChir | University of Cambridge